Alpha 2.0
Login Register
» Authors » Eric M Kanza

Eric M Kanza

Explore the profile of Eric M Kanza including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 84
Followers 0
Related Specialties
General Medicine
Tropical Medicine
Biology
Top 10 Co-Authors
Nicholas O Opoku
Christine M Halleux
Maurice M Nigo
George Olipoh
Sampson Asare
Germain L Mambandu
Annette C Kuesel
Kambale Kataliko
Mupenzi Mumbere
Simon K Attah
Published In
Lancet
Philos Trans R Soc Lond B Biol Sci
PLoS Negl Trop Dis
Parasit Vectors
Mo Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Screening for Eye Disease in Ebola Virus Disease Survivors: Program Implementation During an Active Outbreak in the North Kivu and Ituri Provinces, Democratic Republic of the Congo
Mwanza J, Shantha J, Legand A, Hartley C, Si-Mehand M, Kahatane A, et al.
Int Ophthalmol Clin . 2024 Oct; 64(4):55-61. PMID: 39480208
First identified in the Democratic Republic of the Congo (DRC, formerly Zaire) in 1976, Ebola virus disease (EVD) outbreaks have afflicted thousands of Congolese over the past several decades. The...
2.
Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the...
Kanza E, Nyathirombo A, Larbelee J, Opoku N, Bakajika D, Howard H, et al.
Parasit Vectors . 2024 Mar; 17(1):137. PMID: 38491528
Background: After ivermectin became available, diethylcarbamazine (DEC) use was discontinued because of severe adverse reactions, including ocular reactions, in individuals with high Onchocerca volvulus microfilaridermia (microfilariae/mg skin, SmfD). Assuming long-term...
3.
Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
Kura K, Milton P, Hamley J, Walker M, Bakajika D, Kanza E, et al.
Philos Trans R Soc Lond B Biol Sci . 2023 Aug; 378(1887):20220277. PMID: 37598705
Epidemiological and modelling studies suggest that elimination of transmission (EoT) throughout Africa may not be achievable with annual mass drug administration (MDA) of ivermectin alone, particularly in areas of high...
4.
New Research Aims to Optimize Therapy Against Onchocerciasis
Hong A, Opoku N, Weil G, Kanza E, Gyasi M
Mo Med . 2022 Aug; 119(1):55-59. PMID: 36033145
Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA)...
5.
Effect of a single dose of 8 mg moxidectin or 150 μg/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection
Bakajika D, Kanza E, Opoku N, Howard H, Mambandu G, Nyathirombo A, et al.
PLoS Negl Trop Dis . 2022 Apr; 16(4):e0010079. PMID: 35476631
Background: Our study in CDTI-naïve areas in Nord Kivu and Ituri (Democratic Republic of the Congo, DRC), Lofa County (Liberia) and Nkwanta district (Ghana) showed that a single 8 mg...
6.
Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial
Opoku N, Bakajika D, Kanza E, Howard H, Mambandu G, Nyathirombo A, et al.
Lancet . 2018 Jan; 392(10154):1207-1216. PMID: 29361335
Background: The morbidity and socioeconomic effects of onchocerciasis, a parasitic disease that is primarily endemic in sub-Saharan Africa, have motivated large morbidity and transmission control programmes. Annual community-directed ivermectin treatment...